ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent diseaseNicoletta Colombo, W. Glenn McCluggage, Iain A. McNeish et al.|Annals of Oncology|2019Cited by 1.2k
ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent diseaseJonathan A. Ledermann, Anna Fagotti, Xavier Matías‐Guiu et al.|Annals of Oncology|2024Cited by 277
Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological ResponsesChristian Pfister, Stéphane Culine, Gwénaëlle Gravis et al.|European Urology|2020Cited by 246
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trialSandro Pignata, I. L. Ray-Coquard, Domenica Lorusso et al.|The Lancet Oncology|2021Cited by 148
Interaction between APOE Ɛ4 status, chemotherapy and endocrine therapy on cognitive functioning among breast cancer survivors: the CANTO-Cog longitudinal studyMylène Duivon, Florence Joly, François Christy et al.|Breast Cancer Research|2025Cited by 3